Form 4: Cabaletta Bio's Chief Medical Officer, David J. Chang, Reports Stock Option Grant
SEC Form 4 Filing
David J. Chang, Chief Medical Officer of Cabaletta Bio, Inc., reports the acquisition of stock options.
Summary
- On March 3, 2025, David J. Chang, the Chief Medical Officer of Cabaletta Bio, Inc., acquired stock options.
- The stock options grant him the right to buy 145,000 shares of Cabaletta Bio's common stock at an exercise price of $1.67 per share.
- These options vest over time, with 25% becoming exercisable on March 3, 2026, and the remainder vesting in equal quarterly installments over the following three years, contingent upon continued service.
- Following this transaction, Chang directly owns derivative securities for 145,000 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and indicates confidence in the executive's ability to contribute to the company's success. There are no negative implications.
Positives
- The stock option grant aligns the Chief Medical Officer's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
- The vesting schedule encourages continued service and commitment from the executive.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common practice in the biotechnology industry to attract, retain, and incentivize key executives. This grant is typical for a company of Cabaletta Bio's size and stage.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) used similar equity-based compensation to incentivize their leadership teams.
- The vesting schedule and exercise price are within the typical range for companies of similar market capitalization and growth stage.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns management's interests with the company's performance.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of the stock option transaction. |
| 03/03/2025 | Date the stock options were granted. |
| 03/03/2026 | Date when 25% of the stock options become exercisable. |
| 03/02/2035 | Expiration date of the stock options. |
| 03/04/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.